Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
VANCOUVER, British Columbia, April 18, 2019 — The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF) (Frankfurt:YG3) is pleased to announce it is developing a unique selection of Urban Juve products exclusively for men. Featuring amber and tobacco—two […]
DENVER, March 21, 2019 -Medicine Man Technologies, Inc. (otcqx:MDCL) (“Medicine Man Technologies” or “Company”), a rapidly growing, vertically integrated cannabis operator, today announced it will be presenting at the Sidoti & Company, LLC, Spring 2019 […]
GP Solutions (OTC: GWPD) Interview with Shannon Illingworth, chairman and founder. In this follow-up to our initial interview of March 2019, Shannon talks about how the cannabis industry is […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.